Max Healthcare Institute Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Max Healthcare reported FY25 consolidated revenue from operations of ₹7,02,846 lakhs, up ~30% YoY from ₹5,40,602 lakhs, driven by acquisitions and growth. FY25 PAT stood at ₹1,07,588 lakhs (vs ₹1,05,764 lakhs last year), with Q4 PAT jumping ~26.8% YoY to ₹31,900 lakhs. The board recommended a final dividend of ₹1.5 per share (15% of face value). An exceptional item of ₹7,363 lakhs was booked in Q4 related to the Jaypee Healthcare acquisition (₹625 crore deal completed in Oct-Nov 2024). The company approved a 100-bed expansion at Max Super Speciality Hospital, Nagpur. Deloitte Haskins & Sells issued an unmodified audit opinion, and S.R. Batliboi & Co. LLP will replace them as statutory auditors for FY26-FY30. Operating cash flow remained healthy at ₹1,45,931 lakhs for FY25.
Strong revenue growth reflects successful integration of Jaypee Healthcare, though PAT growth lagged revenue growth due to higher depreciation, finance costs, and the exceptional item. Margin compression is a watchpoint, but strong cash generation, dividend, and expansion plans signal business confidence. Auditor change is a routine 5-year rotation.